Provectus Biopharmaceuticals, Inc. · OTC:PVCT
Provectus Biopharmaceuticals — Shareholder Meeting (June 2026)
24 slides from Provectus Biopharmaceuticals's shareholder meeting presentation, Jun 18, 2026
Slide 1: 2026 Annual Stockholder Meeting
2026 ANNUAL STOCKHOLDER MEETING 0 provectus OTCQB: PVCT biopharmaceuticals Copyright © 2026 Provectus Biopharmaceuticals, Inc.
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS The information in this presentation may include “forward- looking statements” within the meaning of U.S. federal securities legislation and relating to the business of Provectus Biopharmaceuticals, Inc. and its affiliates (Provectus or the Company) that are based on the o
Slide 3: 2026 Annual Stockholder Meeting Agenda
2026 ANNUAL STOCKHOLDER MEETING AGENDA Part 1: Meeting Activities Welcome Part 2: Company Update Opening Remarks Introductions Presentation, Rose Bengal Sodium: A Systems-intelligent Platform Preliminary Matters Q&A Session Order of Business Other Business Report of the Inspector of the Election Con
Slide 4: Part 1: Meeting Activities
ie 7
Slide 5: Meeting Activities
MEETING ACTIVITIES WELCOME INTRODUCTIONS PRELIMINARY MATTERS Inspector of Election Record Date Shares Entitled to Notice & Vote Quorum Reading of the Notice of the Annual Meeting, Affidavit of Mailing, and Minutes Stockholders’ Proxies Stockholders’ Ballots ORDER OF BUSINESS Proposal #1: To elect fo
Slide 6: Part 2: Company Update
Slide 7: Ed Pershing, Chairman & Chief Executive Officer
ED PERSHING, CHAIRMAN & CHIEF EXECUTIVE OFFICER
Slide 8: Rose Bengal Sodium: A Systems-Intelligent Platform
ROSE BENGAL SODIUM: ASYSTEMS-INTELLIGENT PLATFORM A single molecule with the biological intelligence to address disease across multiple organ systems. Presented by Dominic Rodrigues, Vice Chairman & President
Slide 9: The Rose Bengal Sodium (RBS) Molecule
THE ROSE BENGAL SODIUM (RBS) MOLECULE 4 iodine atoms. 4 chlorine atoms. One universal catalyst.
Slide 10: AI-Assisted R&D: Accelerating the Path from Molecule to Medicine
Al-ASSISTED R&D: ACCELERATING THE PATH FROM MOLECULE TO MEDICINE Why Alis critical to Provectus How we currently deploy Al + Target Identification * Mechanism of Action Validation * Cross-Disease Signal Validation + Preclinical and Clinical Data Analysis and Assessment * Strategic Implication: Defin
Slide 11: Injectable Solid Tumors: Intratumoral PV-10
INJECTABLE SOLID TUMORS: INTRATUMORAL PV-10 (IL PV-10) Clinical * Penile SCC * Certain Other Adult Solid Tumors Research * HCC: Collaboration with NIH ClO + Rare Pediatric Cancer: Collaboration with St. Jude’s Children’s Research Hospital (also systemic administration) * Other Clinical: Phase 1-3 St
Slide 12: Ophthalmology: Topical PV-305 + PDAT
OPHTHALMOLOGY: TOPICAL PV-305 + PDAT VisiRose Regulatory + Pre-IND meeting submission (device regulatory included) * Proposed Phase 2b/3 clinical trial design: ¢ Fusarium fungal keratitis ¢ Multiple RB-PDAT cycles Program Updates * Clinical (unaffiliated) + REAGIR Il: bacterial keratitis (NCT0627177
Slide 13: Dermatology: Topical PH-10
DERMATOLOGY: TOPICAL PH-10 8 Ongoing Mechanistic Research * Clinical: Phase 1-2 Psoriasis, Atopic Dermatitis, Actinic Keratosis Implications of Preliminary Findings
Slide 14: Early-Stage Assets
EARLY-STAGE ASSETS PV-10-BASED FORMULATIONS ¢ IND Expansion: Oral PV-10 (and IV PV-10) + Anecdotal Clinical Data + Lead Indication(s) + Bladder Cancer Research Results « Rare Pediatric Cancer (also intratumoral administration) ¢ Wound Healing ¢ Neurodegenerative ¢ Proprietary
Slide 15: Manufacturing
MANUFACTURING Drug Substance / API ‘ox. @) * Clinical: Also PH-10 Current Drug Product Candidates PV-10 O PV-305 ‘ox. CO)
Slide 16: Corporate Development
CORPORATE DEVELOPMENT Planned New Offices Perkins Place Potential Future Activities Potential New Name oor) > Potential Nasdaq Uplisting Strategic & Tactical Option Reverse Split & Reduction in Authorized Shares
Slide 17: Open Science Research & Shareholder Communications
OPEN SCIENCE RESEARCH & SHAREHOLDER COMMUNICATIONS Shareholder & Investor Veripure™ ge P Communications . PRs Open Science Research SEC Filings Program Structure Substack Posts
Slide 18: 2025-2026 Presentations, Publications, Patents & Notable Activity
2025-2026 PRESENTATIONS, PUBLICATIONS, PATENTS, OTHER ACHIEVEMENTS & NOTABLE ACTIVITY June 2025 Data from preclinical research were published in Molecular Cancer Therapeutics: “PV-10 triggers immunogenic cell death in head and neck squamous cell carcinoma via endoplasmic reticulum stress and apoptos
Slide 19: 2025-2026 Presentations, Publications, Patents & Notable Activity
2025-2026 PRESENTATIONS, PUBLICATIONS, PATENTS, OTHER ACHIEVEMENTS & NOTABLE ACTIVITY February 2026 Vials of PV-10 received for preclinical research at National Institutes of Health Clinical Center’s Center for Interventional Oncology on intratumoral PV-10 for hepatocellular carcinoma. Injectable so
Slide 20: Q&A Session
Q&A Session BOARD OF DIRECTORS Webster Bailey Jack Lacey, MD Ed Pershing Dominic Rodrigues
Slide 21: Ed Pershing, Chairman & Chief Executive Officer
ED PERSHING, CHAIRMAN & CHIEF EXECUTIVE OFFICER
Slide 22: Capital Markets Snapshot
CAPITAL MARKETS SNAPSHOT Mailing Address Provectus Biopharmaceuticals, Inc. ; 800 S. Gay St., Suite 1610 Ticker PVCT Knoxville, TN 37929 USA +1 (866) 594-5999 / Fax: +1 (866) 998-0005 Exchange OTCQB Investor Relations Sector Biotechnology investorrelations@pvct.com +1 (866) 594-5999 x1 Media Relatio
Slide 23: Why Invest in Provectus
Clinical trials demonstrating viability of lead cancer immunotherapy candidate PV-10 WHY INVEST IN PROVECTUS Highly experienced & passionate management focused on principled culture building, decision- making, and business strategy execution Open-source network of physician- researchers, scientists,
Slide 24: Slide 24
Provectus Biopharmaceuticals — Shareholder Meeting (June 2026) on 6ix